Skip to main content
. 2024 Jul 12;2(2):qyae067. doi: 10.1093/ehjimp/qyae067

Table 1.

Baseline characteristics of the study population

Clinical features
 Age (years) 46.4 ± 12.5
 Women 412 (84)
 Heart rate (bpm) 70.6 ± 13.9
 Systolic blood pressure (mmHg) 116 ± 16
 Diastolic blood pressure (mmHg) 75 ± 11
 NYHA functional Class III/IV 185 (37.2)
 Previous embolic events 102 (20.7)
 Previous valvuloplastya 159 (32.2)
 Anticoagulation therapy 204 (41.4)
 Sinus rhythm 327 (66.3)
 Atrial fibrillation 166 (33.7)
Echocardiographic data
 LV end-diastolic diameter (mm) 48.4 ± 6.4
 LV end-systolic diameter (mm) 31.8 ± 5.7
 LV ejection fraction (%) 62 ± 7.9
 LA volume (mL/m2) 62 ± 27
 Mitral valve area (cm2) 1.11 ± 0.4
 Mean gradient (mmHg) 10.2 ± 4.9
 SPAP (mmHg) 44.7 ± 18.1
 RV-FAC (%) 46.1 ± 10.3
 TR moderate/severe 82 (16.6)
 Net atrioventricular compliance (Cn) (mL/mmHg) 5.1 ± 1.9
LA strain
 LASr (%) 12.5 ± 7.1
 LAScd (%) 6.7 ± 4.1
 LASct (%) 6.0 ± 4.2

Data are expressed as absolute numbers (percentage) or the mean value ± standard deviation.

FAC, right ventricular fractional area change; LA, left atrial; LAScd, left atrial strain during the conduit phase; LASct, Left atrial strain during the contractile phase; LASr, left atrial strain during the reservoir phase; LV, left ventricular; NYHA, New York Heart Association; SPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation.

aSurgical commissurotomy or percutaneous valvuloplasty in the past [85 patients (16.9%) percutaneous valvuloplasty, 58 patients (11.5%) surgical commissurotomy; 16 patients (3.2%) both surgical and percutaneous valvuloplasty].